The industry’s focus on living organisms of the human species and the strict regulations that it imposes are unique to business leaders. These characteristics make the industry an ideal incubator for technological innovation, resulting in major genotec-frankfurt.de breakthroughs that have improved the yield of agricultural crops, developed biofuels and helped to create life-saving pharmaceutical products.
Biotech startups have a myriad of options for revenue generation strategies, with the majority opting for either a technology partnering or an approach to asset creation and out-licensing. Technology partnering can bring faster revenue and lower financial risk, whereas assets creation and outlicensing strategies are able to yield much greater returns. A growing number of biotechs in the research stage operate in a hybrid approach that combines both strategies.
If you choose to go with an approach to development that is oriented towards product will succeed commercially when they get their pipeline to the right stage and attract a large pharmaceutical partner or an investor with a large sum of money. This could be costly however, and managing opportunistic approaches to leverage outside resources with the right research-based decision making about homegrown projects is essential.
The “platform” model is a second option to generate revenue. It’s a lower-cost route than the product-oriented development however it carries substantial risk. In this model, a biotech is the owner and develops its platform technology, before joining with major pharma companies to create a portfolio of drug discovery projects that are targeted at specific disease areas (i.e., disease the x gene within biology y). This is the approach that Advinus Therapeutics and a few others have taken.